FDA Approves New Technique To Extend Supply Of Monkeypox Vaccine: Report
A plan to extend the limited supply of monkeypox vaccine in order to provide additional doses has been approved by the Food and Drug Administration.
Atara Lays Off 20% Of Its Workforce, Issues Update On Cell Therapies
Atara Biotherapeutics Inc (NASDAQ:ATRA) will reduce cash burn by laying off 20% of its staff and extend the cash…
Amazon Receives FDA Warning Letter For OTC Mole Removal Products
The FDA’s Center for Drug Evaluation and Research released a warning letter sent to Amazon Inc’s (NASDAQ:AMZN) CEO Andy Jassy for selling…
Heron Shares Jump After Equity Financing, Q2 Earnings
Heron Therapeutics Inc (NASDAQ:HRTX) reported Q2 sales of $27.63 million, +23.1% Y/Y, beating the consensus of $24.31 million. Oncology sales…
Endo Shares Plunge On Imminent Bankruptcy Filing
Endo International plc’s (NASDAQ:ENDP) Q2 sales decreased 20% to $569.11 million, beating the consensus of $529.94 million. The decrease was…
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) non-opioid painkiller. The company…
Merck Re-enters Alzheimer’s R&D With Research Pact With Cerevance
Cerevance, a private, clinical-stage drug discovery and development company, announced a multi-year strategic research collaboration with Merck & Co Inc (NYSE:MRK). The…
NeuroOne Medical Shares Fall After EEG Electrode Regulatory Update
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has submitted a special 510(k) to the FDA for its sEEG electrode to extend the duration…
NeuroOne Seeks Again FDA Clearance For sEEG Electrode In Brain Mapping Diagnostics
NeuroOne Medical Technologies (NASDAQ: NMTC) has submitted a special 510(k) to the U.S. Food and Drug Administration (FDA) for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.
FDA Pushes Decision Date For Reata’s Genetic Neuromuscular Disease Candidate
The FDA has extended the review timeline for Reata Pharmaceuticals Inc’s (NASDAQ:RETA) marketing application seeking approval for omaveloxolone for Friedreich’s ataxia by…